Last Updated: August 9, 2026

Details for New Drug Application (NDA): 213155

✉ Email this page to a colleague

« Back to Dashboard

NDA 213155 describes LIRAGLUTIDE, which is a drug marketed by Biocon Pharma, Fresenius Kabi Usa, Hikma, Lupin, Mylan Institutional, Nanjing King Friend, Orbicular, Sandoz, and Teva Pharms, and is included in eleven NDAs. It is available from nine suppliers. Additional details are available on the LIRAGLUTIDE profile page.

The generic ingredient in LIRAGLUTIDE is liraglutide. There are seven drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the liraglutide profile page.

Summary for 213155

Tradename:	LIRAGLUTIDE
Applicant:	Mylan Institutional
Ingredient:	liraglutide
Patents:	0

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;SUBCUTANEOUS			Strength	18MG/3ML (6MG/ML)
Approval Date:	Jun 15, 2026	TE:	AP1	RLD:	No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.